-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 O9fpsaxLIRmAa9IDA6hvhcq35XS1NGe3IeChqGw2WZK5GqOFC4fj56Mxf1/kefFZ
 7hOZVpv4qDCEPi0vGb1B3A==

<SEC-DOCUMENT>0000950136-07-004893.txt : 20070713
<SEC-HEADER>0000950136-07-004893.hdr.sgml : 20070713
<ACCEPTANCE-DATETIME>20070713171103
ACCESSION NUMBER:		0000950136-07-004893
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070713
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070713
DATE AS OF CHANGE:		20070713

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		07979208

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			21000
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			21000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>file1.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>
</TITLE>
</HEAD>
<BODY>


   <PAGE>
	 <DIV
	  STYLE="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

	 <DIV
	  STYLE="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>

	 <P STYLE="font-size: 14pt; margin-top: 12pt; text-align: center">
		<B>UNITED STATES<BR>SECURITIES AND EXCHANGE COMMISSION</B>
	 </P>
	 <P STYLE="font-size: 12pt; text-align: center; margin-top:-14pt">
		<B>WASHINGTON, D.C. 20549</B>
	 </P>
	 <DIV ALIGN="center">
		<P
		 STYLE="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000"
		 ALIGN="center">
		  &nbsp;
		</P>
	 </DIV>
	 <P STYLE="font-size: 18pt; margin-top: 12pt; text-align: center">
		<B>FORM 8-K</B>
	 </P>
	 <P STYLE="font-size: 12pt; margin-top: 12pt; text-align: center">
		<B>CURRENT REPORT PURSUANT<BR> TO SECTION 13 OR 15(d) OF THE<BR>
		SECURITIES EXCHANGE ACT OF 1934</B>
	 </P>
	 <P STYLE="font-size: 10pt; margin-top: 16pt; text-align:center">
		Date of report (Date of earliest event reported):<B> July 13, 2007</B>
	 </P>
	 <P STYLE="font-size: 24pt; margin-top: 10pt; text-align:center">
		<B>Protalix BioTherapeutics, Inc.</B>
	 </P>
	 <P STYLE="font-size: 10pt; text-align:center; margin-top: -16pt">
		(Exact Name of Registrant as Specified in Its Charter)
	 </P>
	 <P STYLE="font-size: 10pt; margin-top: 2pt; text-align: center">
		<B>Florida</B>
	 </P>
	 <P
	  STYLE="font-size: 10pt; margin-top: -16pt; margin-bottom: -1pt; text-align:center">
		(State or Other Jurisdiction of Incorporation)
	 </P>
	 <TABLE STYLE="font-size: 10pt" CELLSPACING="0" BORDER="0" CELLPADDING="0"
	  WIDTH="100%">
		<TR VALIGN="bottom">
		  <TD WIDTH="47%">&nbsp;</TD>
		  <TD WIDTH="5%">&nbsp;</TD>
		  <TD WIDTH="47%">&nbsp;</TD>
		</TR>
		<TR VALIGN="bottom">
		  <TD ALIGN="center" VALIGN="top"><B>000-27836</B><BR> (Commission File
			 Number) </TD>
		  <TD>&nbsp;</TD>
		  <TD ALIGN="center" VALIGN="top"><B>65-0643773</B><BR> (IRS Employer
			 Identification No.)</TD>
		</TR>
		<TR VALIGN="bottom">
		  <TD ALIGN="center" VALIGN="top">&nbsp;</TD>
		  <TD>&nbsp;</TD>
		  <TD ALIGN="center" VALIGN="top">&nbsp;</TD>
		</TR>
		<TR VALIGN="bottom">
		  <TD ALIGN="center" VALIGN="top"><B>2 Snunit Street Science Park POB 455
			 Carmiel, Israel </B><BR> (Address of Principal Executive Offices) </TD>
		  <TD>&nbsp;</TD>
		  <TD ALIGN="center" VALIGN="top"><B>21000</B><BR> (Zip Code)</TD>
		</TR>
	 </TABLE>
	 <P STYLE="font-size: 10pt; margin-top: 12pt; text-align: center">
		<B>+972-4-988-9488</B><BR> (Registrant&#146;s Telephone Number, Including
		Area Code)
	 </P>
	 <P STYLE="font-size: 10pt; margin-top: 18pt; text-align:center">
		<FONT STYLE="border-top: 1px solid #000000">(Former Name or Former
		Address, if Changed Since Last Report)</FONT>
	 </P>
	 <DIV ALIGN="center">
		<DIV
		 STYLE="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV>
		</DIV>
	 <P
	  STYLE="font-size: 10pt; margin-top: 6pt; margin-bottom: 6pt; text-align:left">
		Check the appropriate box below if the Form 8-K filing is intended to
		simultaneously satisfy the filing obligation of the registrant under any of the
		following provisions (see General Instruction A.2. below):
	 </P>
	 <TABLE WIDTH="100%" BORDER="0" CELLPADDING="0" CELLSPACING="0"
	  STYLE="font-size: 10pt">
		<TR VALIGN="top"
		 STYLE="font-size: 10pt; color: #000000; background: transparent">
		  <TD WIDTH="3%" NOWRAP="NOWRAP" ALIGN="left"><FONT
			 FACE="Wingdings">o</FONT></TD>
		  <TD WIDTH="1%">&nbsp;</TD>
		  <TD>Written communications pursuant to Rule 425 under the Securities
			 Act (17 CFR 230.425)</TD>
		</TR>
		<TR>
		  <TD STYLE="font-size: 6pt">&nbsp;</TD>
		</TR>
		<TR VALIGN="top"
		 STYLE="font-size: 10pt; color: #000000; background: transparent">
		  <TD WIDTH="3%" NOWRAP="NOWRAP" ALIGN="left"><FONT
			 FACE="Wingdings">o</FONT></TD>
		  <TD WIDTH="1%">&nbsp;</TD>
		  <TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act
			 (17 CFR 240.14a -12)</TD>
		</TR>
		<TR>
		  <TD STYLE="font-size: 6pt">&nbsp;</TD>
		</TR>
		<TR VALIGN="top"
		 STYLE="font-size: 10pt; color: #000000; background: transparent">
		  <TD WIDTH="3%" NOWRAP="NOWRAP" ALIGN="left"><FONT
			 FACE="Wingdings">o</FONT></TD>
		  <TD WIDTH="1%">&nbsp;</TD>
		  <TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the
			 Exchange Act (17 CFR 240.14d -2(b))</TD>
		</TR>
		<TR>
		  <TD STYLE="font-size: 6pt">&nbsp;</TD>
		</TR>
		<TR VALIGN="top"
		 STYLE="font-size: 10pt; color: #000000; background: transparent">
		  <TD WIDTH="3%" NOWRAP="NOWRAP" ALIGN="left"><FONT
			 FACE="Wingdings">o</FONT></TD>
		  <TD WIDTH="1%">&nbsp;</TD>
		  <TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the
			 Exchange Act (17 CFR 240.13e-4(c))</TD>
		</TR>
	 </TABLE>
	 <DIV
	  STYLE="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>

	 <DIV
	  STYLE="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:left;">
		<FONT STYLE="font-size:10pt">&nbsp;</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:left;">
		<FONT STYLE="font-size:10pt">&nbsp;</FONT>
	 </P>
<!-- EEDocs PBStart--><HR NOSHADE="NOSHADE" ALIGN="center" WIDTH="100%"
	 SIZE="2">
	 <P STYLE="page-break-before:always">
	 </P>
	 <PAGE>
<!-- EEDocs PBEnd-->
	 <P STYLE=" margin-bottom:0pt; margin-top:12pt;text-align:left;">
		<B><FONT STYLE="font-size:10pt">Item 8.01. Other Events</FONT></B>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:8pt;text-align:left;">
		<FONT STYLE="font-size:10pt">On July 13, 2007, Protalix BioTherapeutics,
		Inc. (the &#147;Company&#148;) issued a press release announcing that it had
		reached an agreement with the United States Food and Drug Administration on the
		design of the Company&#146;s phase III clinical trial of prGCD for the
		treatment of Gaucher disease, through the FDA&#146;s special protocol
		assessment (SPA) process. The press release is attached hereto as Exhibit
		99.1.</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:12pt;text-align:left;">
		<B><FONT STYLE="font-size:10pt">Item 9.01. Financial Statements and
		Exhibits</FONT></B>
	 </P>
	 <DIV ALIGN="left">
		<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%"
		 STYLE=" border-collapse:collapse;">
		  <TR>
			 <TD WIDTH="5%" VALIGN="top" STYLE="padding:6.0pt 0in 0in 0in;">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;">
				  <B><FONT STYLE="font-size:10pt">(d)</FONT></B>
				</P>
			 </TD>
			 <TD VALIGN="top" STYLE="padding:6.0pt 0in 0in 0in;">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;">
				  <B><FONT STYLE="font-size:10pt">Exhibits </FONT></B>
				</P>
			 </TD>
		  </TR>
		</TABLE> </DIV>
	 <DIV ALIGN="left">
		<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%"
		 STYLE=" border-collapse:collapse;">
		  <TR>
			 <TD WIDTH="5%" VALIGN="top" STYLE="padding:6.0pt 0in 0in 0in;">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;">
				  <FONT STYLE="font-size:10pt">99.1</FONT>
				</P>
			 </TD>
			 <TD VALIGN="top" STYLE="padding:6.0pt 0in 0in 0in;">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt;">
				  <FONT STYLE="font-size:10pt">Press release dated July 13,
				  2007.</FONT>
				</P>
			 </TD>
		  </TR>
		</TABLE> </DIV>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:left;">
		<FONT STYLE="font-size:12pt">&nbsp;</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:center;">
		<FONT STYLE="font-size:10pt">2</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:left;">
		<FONT STYLE="font-size:12pt">&nbsp;</FONT>
	 </P>
<!-- EEDocs PBStart--><HR NOSHADE="noshade" ALIGN="center" WIDTH="100%"
	 SIZE="2">
	 <P STYLE="page-break-before:always">
	 </P>
	 <PAGE>
<!-- EEDocs PBEnd-->
	 <P STYLE=" margin-bottom:0pt; margin-top:16pt;text-align:center;">
		<B><FONT STYLE="FONT-SIZE:10PT">SIGNATURES</FONT></B>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:8pt;text-align:left;">
		<FONT STYLE="font-size:10pt">Pursuant to the requirements of the
		Securities Exchange Act of 1934, the Registrant has duly caused this report to
		be signed on its behalf by the undersigned hereunto duly authorized.</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:left;">
		<FONT STYLE="font-size:10pt">&nbsp;</FONT>
	 </P>
	 <DIV ALIGN="center">
		<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH="100%"
		 STYLE=" border-collapse:collapse;">
		  <TR>
			 <TD VALIGN="bottom">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;">
				  <FONT STYLE="font-size:10pt">&nbsp;</FONT>
				</P>
			 </TD>
			 <TD VALIGN="bottom">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;">
				  <FONT STYLE="font-size:10pt">&nbsp;</FONT>
				</P>
			 </TD>
			 <TD COLSPAN="2" VALIGN="bottom">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;">
				  <B><FONT STYLE="FONT-SIZE:10PT">PROTALIX BIOTHERAPEUTICS,
				  INC.</FONT></B>
				</P>
			 </TD>
		  </TR>
		  <TR>
			 <TD WIDTH="49%" VALIGN="bottom">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;">
				  <BR> <FONT STYLE="font-size:10pt">Date: July 13, 2007</FONT>
				</P>
			 </TD>
			 <TD WIDTH="7%" VALIGN="bottom">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;">
				  <FONT STYLE="font-size:10pt">&nbsp;</FONT>
				</P>
			 </TD>
			 <TD WIDTH="4%" VALIGN="bottom">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;">
				  <FONT STYLE="font-size:10pt">By:&nbsp;</FONT>
				</P>
			 </TD>
			 <TD WIDTH="40%" VALIGN="bottom"
			  STYLE="border-bottom: solid black .5pt;">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;">
				  <BR> <FONT STYLE="font-size:10pt">/s/ David Aviezer</FONT>
				</P>
			 </TD>
		  </TR>
		  <TR>
			 <TD VALIGN="top">&nbsp;</TD>
			 <TD VALIGN="top">&nbsp;</TD>
			 <TD VALIGN="top"><FONT STYLE="font-size:10pt">Name:&nbsp;</FONT></TD>

			 <TD VALIGN="top"><FONT STYLE="font-size:10pt">David Aviezer,
				Ph.D.</FONT></TD>
		  </TR>
		  <TR>
			 <TD VALIGN="top">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;">
				  <FONT STYLE="font-size:10pt">&nbsp;</FONT>
				</P>
			 </TD>
			 <TD VALIGN="top">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;">
				  <FONT STYLE="font-size:10pt">&nbsp;</FONT>
				</P>
			 </TD>
			 <TD VALIGN="top">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;">
				  <FONT STYLE="font-size:10pt">Title:&nbsp;</FONT>
				</P>
			 </TD>
			 <TD VALIGN="top">
				<P
				 STYLE=" margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:0pt;">
				  <FONT STYLE="font-size:10pt">President and</FONT><BR>
				  <FONT STYLE="font-size:10pt">Chief Executive Officer</FONT>
				</P>
			 </TD>
		  </TR>
		</TABLE> </DIV>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:left;">
		<FONT STYLE="font-size:10pt">&nbsp;</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:center;">
		<FONT STYLE="font-size:10pt">3</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:left;">
		<FONT STYLE="font-size:12pt">&nbsp;</FONT>
	 </P>
<!-- EEDocs PBStart--><HR NOSHADE="noshade" ALIGN="center" WIDTH="100%"
	 SIZE="2">
	 <P STYLE="page-break-before:always">
	 </P>


</BODY>
</HTML>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>file2.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>
</TITLE>
</HEAD>
<BODY>


   <PAGE>
<!-- EEDocs PBEnd-->
	 <P STYLE=" margin-bottom:0pt; margin-top:8pt;text-align:right;">
		<FONT STYLE="font-size:10pt">Exhibit 99.1</FONT>
	 </P>

	 <P STYLE=" margin-bottom:0pt; margin-top:16pt;text-align:center;">
		<B><FONT STYLE="font-size:10pt">Protalix BioTherapeutics, Inc. Receives
		Special Protocol Assessment Approval from </FONT></B>
	 </P>

	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:center;">
		<B><FONT STYLE="font-size:10pt">FDA for its Phase III Clinical Study of
		prGCD</FONT></B>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:16pt;text-align:center;">
		<I><FONT STYLE="font-size:10pt">Company Expects to Begin Enrolling
		</FONT><FONT STYLE="font-size:10.5pt">Gaucher Disease</FONT><FONT
		STYLE="font-size:10pt"> Patients for Phase III Clinical Trials</FONT></I>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:center;">
		<I><FONT STYLE="font-size:10pt">of prGCD in Third Quarter of 2007
		</FONT></I>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:8pt;text-align:left;">
		<FONT STYLE="font-size:10pt">Carmiel, Israel &#150; July 13, 2007 -
		Protalix BioTherapeutics, Inc. (AMEX: PLX) today announced that it has reached
		an agreement with the United States Food and Drug Administration on the final
		design of its pivotal phase III clinical trial for its lead product candidate,
		prGCD, through the FDA&#146;s Special Protocol Assessment (SPA) process. The
		Company expects to initiate enrollment of patients for its phase III clinical
		trials during the third quarter of 2007.</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:8pt;text-align:left;">
		<FONT STYLE="font-size:10pt">prGCD is a proprietary plant cell expressed
		recombinant form of human Glucocerebrosidase (GCD), for the treatment of
		Gaucher disease, a lysosomal storage disorder in humans. </FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:8pt;text-align:left;">
		<FONT STYLE="font-size:10pt">The phase III clinical trial will take place
		in leading medical centers in the United States, Israel, where approval from
		the Israeli Ministry of Health has been received, and other locations
		worldwide. The clinical trial will initially consist of male and female adult
		patients with Gaucher disease.</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:12pt;text-align:left;">
		<B><FONT STYLE="font-size:10pt">About Protalix BioTherapeutics,
		Inc.</FONT></B>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:8pt;text-align:left;">
		<FONT STYLE="font-size:10pt">Protalix is a clinical stage
		biopharmaceutical company. Its goal is to become a fully integrated
		biopharmaceutical company focused on focused on the development and
		commercialization of proprietary recombinant therapeutic proteins to be
		expressed through its proprietary plant cell based expression system.
		Protalix&#146;s ProCellEx<SUP>TM</SUP> presents a proprietary method for the
		expression of recombinant proteins that Protalix believes is safe and scalable
		and will allow for the cost-effective, industrial-scale production of
		recombinant therapeutic proteins. Protalix has recently announced that it has
		received written notice from the United States Food and Drug Administration
		that it may initiate a phase III clinical trial in the United States of its
		lead product candidate, prGCD, for its enzyme replacement therapy for Gaucher
		disease, a lysosomal storage disorder in humans. Protalix is also advancing
		additional recombinant biopharmaceutical drug development programs.</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:12pt;text-align:left;">
		<B><FONT STYLE="font-size:10pt">Safe Harbor Statement:</FONT></B>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:8pt;text-align:left;">
		<FONT STYLE="font-size:10pt">To the extent that statements in this press
		release are not strictly historical, all such statements are forward-looking,
		and are made pursuant to the safe-harbor provisions of the Private Securities
		Litigation Reform Act of 1995. These forward-looking statements are subject to
		known and unknown risks and uncertainties that may cause actual future
		experience and results to differ materially from the statements made. These
		statements are based on our current beliefs and expectations as to such future
		outcomes. Drug discovery and development involve a high degree of risk. Factors
		that might cause such a material difference include, among others, the inherent
		risks and uncertainties in developing drug platforms and products of the type
		we are developing; delays in our preparation and filing of applications for
		regulatory approval; delays in the approval or potential rejection of any
		applications we file with the FDA, or other health regulatory authorities; any
		lack of progress of our research and development (including the results of
		clinical trials being conducted by us); obtaining on a timely basis sufficient
		patient enrollment in our clinical trials; the impact of development of
		competing therapies and/or technologies by other companies; our ability to
		obtain additional financings required to fund our research programs; our
		ability to establish and maintain strategic license, collaboration and
		distribution arrangements and to manage our relationships with collaborators,
		distributors and partners; potential product liability risks and risks of
		securing adequate levels of product liability and clinical trial insurance
		coverage; the possible disruption of our operations due to terrorist activities
		and armed conflict, including as a result of the disruption of operations of
		regulatory authorities, our subsidiaries, our manufacturing facilities and our
		customers, suppliers, distributors, couriers, collaborative partners,
		licensees, and clinical trial sites; and other factors described in our filings
		with the Securities and Exchange Commission. The statements are valid only as
		of the date hereof and we disclaim any obligation to update this information.
		</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:left;">
		<FONT STYLE="font-size:12pt"><A NAME="dv_x0"></A>&nbsp;</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:12pt;text-align:left;">
		<B><FONT STYLE="font-size:10pt">For additional information,
		contact:</FONT></B>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:8pt;text-align:left;">
		<FONT STYLE="font-size:10pt">Protalix Investor relations:
		investors@protalix.com </FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:8pt;text-align:left;">
		<FONT STYLE="font-size:10pt">AMEX IR Alliance for Protalix:</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:left;">
		<FONT STYLE="font-size:10pt">Lee Roth / David Burke</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:left;">
		<FONT STYLE="font-size:10pt">212-896-1209 / 212-896-1258</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:left;">
		<FONT STYLE="font-size:10pt"><U>lroth@kcsa.com</U> /
		dburke@kcsa.com</FONT>
	 </P>
	 <P STYLE=" margin-bottom:0pt; margin-top:0pt;text-align:left;">
		<FONT STYLE="font-size:12pt">&nbsp;</FONT>
	 </P>
<!-- EEDocs PBStart--><HR NOSHADE="noshade" ALIGN="center" WIDTH="100%"
	 SIZE="2">
<!-- EEDocs PBEnd-->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
